Funded in part by Takeda Pharmaceuticals U.S.A.
Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases
Winter RW, Collins E, Cao B, Carrellas M, Crowell AM, Korzenik JR
Alimentary pharmacology & therapeutics · 63 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Cohort study (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Company
- Takeda Pharmaceuticals U.S.A.
- Government
- National Institutes of Health
- Government
- National Institute of Diabetes and Digestive and Kidney Diseases
- Government
- NIDDK NIH HHS
- Grants
- National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK007533); National Institutes of Health (T32 DK007533-29)
Based on 4 listed funder(s).
Publication
- Published
- 2017-01-10 · Aliment Pharmacol Ther · vol. 45 · issue 5 · pp. 653–659
- Publisher
- Wiley
- Cited
- 74 citations · more than 97% of similar papers · 6.3× the field average
- Impact
- Top 10% most cited in its field
- References
- 19 works
- Access
- Open access (repository copy)
- Research areas
- Vitamin D Research Studies · Inflammatory Bowel Disease · Vitamin C and Antioxidants Research
- Keywords
- Medicine, Inflammatory Bowel Diseases, Internal medicine, Gastroenterology, Odds ratio, Inflammatory bowel disease, Tumor necrosis factor alpha, Necrosis, Odds, Risk factor, Tumor necrosis factor α, Logistic regression, Disease
- MeSH
- humans, inflammatory bowel diseases, vitamin d, tumor necrosis factor-alpha, logistic models, retrospective studies, adult, middle aged, female, male, young adult, adalimumab, infliximab
6 authors
From US
- Rachel W. Winter · correspondingBrigham and Women's Hospital
- Emily CollinsBrigham and Women's Hospital
- Bangping CaoBrigham and Women's Hospital
- Madeline CarrellasBrigham and Women's Hospital
- Anne Marie CrowellBrigham and Women's Hospital
- Joshua R. KorzenikBrigham and Women's Hospital
Abstract
Background
Vitamin D has been linked to disease activity among patients with inflammatory bowel diseases (IBD). Prior investigation has also suggested that vitamin D levels may affect duration of therapy with anti-tumour necrosis factor-α (anti-TNF-α) medications among patients with IBD.
Aim
To evaluate the relationship between vitamin D levels and odds of reaching remission while on an anti-TNF-α medication.
Methods
A total of 521 IBD patients enrolled in the Brigham and Women's IBD Centre database were eligible for inclusion. Patients treated with anti-TNF-α therapy who had vitamin D levels drawn within 6 months prior or 2 weeks after initiation of anti-TNF-α medication and who had reported remission status at 3 months were included. A logistic regression model adjusting for age, gender, IBD diagnosis, anti-TNF-α medication (infliximab vs. adalimumab) and first or subsequent anti-TNF-α medication was used to identify the effect of vitamin D level on initial response to anti-TNF-α therapy.
Results
A total of 173 patients were included in the final analysis. On logistic regression, patients with normal vitamin D levels n = 122 at the time of anti-TNF-α medication initiation had a 2.64 increased odds of remission at 3 months compared to patients with low vitamin D levels n = 51 when controlling for age, gender, diagnosis, type of anti-TNF-α medication and first or subsequent anti-TNF-α medication (OR = 2.64, 95% CI = 1.31-5.32, P = 0.0067).
Conclusions
These findings suggest that vitamin D levels may influence initial response to anti-TNF-α medication and that low vitamin D levels may pre-dispose patients to decreased odds of remission.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.